More Acquisitions: #MisfitsMarket > #TheRounds; #NWN > #InterVisionSystems; #QuantumHealth > #EmboldHealth; #Salesforce > #Informatica; #Sanofi > #BlueprintMedicines; #Scopely > #Niantic; #Snowflake > #CrunchyData; #Zscaler > #RedCanary

Merger: #Cormi.com & #Doss

Sanofi neemt Blueprint Medicines over voor 9,1 miljard dollar Key takeaways Sanofi heeft overeenstemming bereikt over de overname van Blueprint Medicines, een biofarmaceutisch bedrijf dat zich specialiseert in behandelingen voor systemische mastocytose (SM), een zeldzame immunologische ziekte die wordt veroorzaakt door KIT-genmutaties. Deze overname versterkt Sanofi’s immunologieportfolio door toevoeging van Ayvakit/Ayvakyt, het enige goedgekeurde geneesmiddel voor gevorderde en indolente SM, en een veelbelovende pijplijn […]

Sanofi neemt Blueprint Medicines over voor 9,1 miljard dollar #Sanofi #BlueprintMedicines #overname #biotechnologie #immunologie

Sanofi acquiert Blueprint Medicines pour 9,1 milliards de dollars Principaux renseignements Sanofi a convenu d’acquérir Blueprint Medicines, une société biopharmaceutique spécialisée dans les traitements de la mastocytose systémique (SM), une maladie immunologique rare due à des mutations du gène KIT. Cette acquisition renforce le portefeuille de Sanofi dans le domaine de l’immunologie en y ajoutant Ayvakit/Ayvakyt, le seul médicament approuvé pour le traitement de […]

Sanofi acquiert Blueprint Medicines pour 9,1 milliards de dollars #Sanofi #BlueprintMedicines #Acquisition #Immunologie #Pharmaceutique

Cleveland-Cliffs, Tesla, Blueprint Medicines, Moderna, BioNTech, DraftKings, and More Movers - Barron's Cleveland-Cliffs, Tesla, Blueprint Medicines, Moderna, BioNTech, DraftKings, and More Movers  Barron's

Click Subscribe #ClevelandCliffs #Tesla #BlueprintMedicines #Moderna #BioNTech

Sanofi to buy US biopharma group Blueprint for up to $9.5 billion France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.

Sanofi will acquire U.S.-based Blueprint Medicines for up to $9.5B to expand in rare immunology. The deal includes Ayvakit for systemic mastocytosis, plus pipeline treatments elenestinib and BLU-808. Closing expected Q3.

#Sanofi #BlueprintMedicines #RareDisease #Immunology #PharmaNews

Sanofi to buy Blueprint Medicines for $9.1 bln Sanofi will pay $129.0 in cash for each share in Blueprint, representing an equity value of $9.1 billion. The figure is also a 27.3% premium to Blueprint’s Friday close. Sanofi also offered Blueprint shareholders two separate contingent value right payments of $2 and $4, contingent on future regulatory developments of BLU-808, a pipeline immunology drug being developed by Blueprint. The two had entered an agreement regarding the takeover, with the total equity value of the transaction being $9.5 billion. Acquiring Blueprint’s portfolio of immunology treatments was cited as the main motivator behind Sanofi’s offer, with Sanofi highlighting Blueprint’s Ayvakit/Ayvajyt drug, as well as a “promising advanced and early-stage immunology pipeline.” Sanofi also said that Blueprint’s presence in allergists, dermatologists, and immunologists will enhance the former’s “growing immunology pipeline.” Should you invest $2,000 in SASY right now? With SASY making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed SASY alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including SASY, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is SASY poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #Sanofi #BlueprintMedicines #Pharmaceuticals #MergersAndAcquisitions #Investing

Sanofi set to buy Blueprint Medicines, broadening immunology portfolio Sanofi will pay $129.00 per share in cash at closing, which translates to an equity value of approximately $9.1 billion for Blueprint Medicines. This move will extend Sanofi’s portfolio in the area of rare immunological diseases and add an early-stage pipeline in immunology. The acquisition is planned to be financed through a combination of cash and new debt. Sanofi aims to finalize the deal in the third quarter of 2025. The deal is expected to immediately increase Sanofi’s gross margin. Blueprint shareholders are set to receive one non-tradeable Contingent Value Right (CVR). This CVR will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR, respectively, upon the achievement of future development and regulatory milestones for BLU-808. If these potential CVR payments are included, the total equity value of the Blueprint transaction represents approximately $9.5 billion on a fully diluted basis. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Sanofi #BlueprintMedicines #Immunology #Pharmaceuticals #Biotech